S M Curkendall

Summary

Affiliation: Cerner Corporation
Country: USA

Publications

  1. ncbi Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients
    Suellen M Curkendall
    Cerner Health Insights, Vienna, VA 22182, USA
    Ann Epidemiol 16:63-70. 2006
  2. ncbi Cardiovascular disease in patients with schizophrenia in Saskatchewan, Canada
    Suellen M Curkendall
    Healthcare Data Analysis, Vienna, VA 22180, USA
    J Clin Psychiatry 65:715-20. 2004
  3. ncbi Chronic obstructive pulmonary disease severity and cardiovascular outcomes
    Suellen M Curkendall
    Cerner LifeSciences, 1953 Gallows Road, Suite 570, Vienna, VA 22182, USA
    Eur J Epidemiol 21:803-13. 2006
  4. ncbi Incidence of anaemia among HIV-infected patients treated with highly active antiretroviral therapy
    S M Curkendall
    Cerner LifeSciences, Vienna, VA 22180, USA
    HIV Med 8:483-90. 2007
  5. ncbi Compliance with biologic therapies for rheumatoid arthritis: do patient out-of-pocket payments matter?
    S Curkendall
    Cerner LifeSciences, Beverly Hills, California, USA
    Arthritis Rheum 59:1519-26. 2008

Detail Information

Publications5

  1. ncbi Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients
    Suellen M Curkendall
    Cerner Health Insights, Vienna, VA 22182, USA
    Ann Epidemiol 16:63-70. 2006
    ..To measure prevalence, incidence, and mortality of cardiovascular outcomes among persons with chronic obstructive pulmonary disease (COPD) and to assess the extent these outcomes differ from persons without COPD...
  2. ncbi Cardiovascular disease in patients with schizophrenia in Saskatchewan, Canada
    Suellen M Curkendall
    Healthcare Data Analysis, Vienna, VA 22180, USA
    J Clin Psychiatry 65:715-20. 2004
    ..However, population-based data on the prevalence, incidence, and mortality of cardiovascular disease are needed...
  3. ncbi Chronic obstructive pulmonary disease severity and cardiovascular outcomes
    Suellen M Curkendall
    Cerner LifeSciences, 1953 Gallows Road, Suite 570, Vienna, VA 22182, USA
    Eur J Epidemiol 21:803-13. 2006
    ..To identify predictors of chronic obstructive pulmonary disease (COPD) severity and assess the relation between COPD severity and risk of cardiovascular outcomes...
  4. ncbi Incidence of anaemia among HIV-infected patients treated with highly active antiretroviral therapy
    S M Curkendall
    Cerner LifeSciences, Vienna, VA 22180, USA
    HIV Med 8:483-90. 2007
    ..The aim of the study was to compare the incidence of anaemia in patients treated with zidovudine (ZDV) with that in patients treated with highly active antiretroviral therapy (HAART) not including ZDV...
  5. ncbi Compliance with biologic therapies for rheumatoid arthritis: do patient out-of-pocket payments matter?
    S Curkendall
    Cerner LifeSciences, Beverly Hills, California, USA
    Arthritis Rheum 59:1519-26. 2008
    ..To assess the impact of patient out-of-pocket (OOP) expenditures on adherence and persistence with biologics in patients with rheumatoid arthritis (RA)...